Our study also showed that the role of MYH9 in ccRCC was partially associated with its ability to activate AKT signaling pathway, since it was well documented that the effects of inhibiting ccRCC of shMYH9 could be reversed by AKT agonist. This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.